Updated:
Mirna Therapeutics
Mirna Therapeutics develops microRNA-based therapies for oncology. The company targets solid and hematologic cancers using miRNA technology to replace or...
Mirna Therapeutics
Mirna Therapeutics develops microRNA-based therapies for oncology. The company targets solid and hematologic cancers using miRNA technology to replace or restore microRNA function. Founded in 2007, Mirna Therapeutics is based in Austin, Texas.
General information
Firm type
other
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Additional offices
Cambridge, United Kingdom · Menlo Park, United States · New York, United States · Seattle, United States · Austin, United States · San Diego, United States
Frequently asked questions
Who runs investment decisions at Mirna Therapeutics?
No named principals or investment decision-makers are publicly traceable for Mirna Therapeutics. The firm's leadership team is not disclosed on its website or in any public source. This absence of disclosure limits external due diligence.
What is the wealth origin behind Mirna Therapeutics?
The wealth origin of Mirna Therapeutics is not publicly disclosed. No family, principal, or institutional source of capital is attributable in any public record. The firm remains opaque regarding its funding base.
Does Mirna Therapeutics participate in fund commitments or direct deals?
Mirna Therapeutics does not publicly disclose its investment structure, including whether it commits to funds, engages in direct deals, or co-invests alongside external GPs. No associated portfolio companies or deals are documented in public sources.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: